"For some time there have been two schools of thought regarding oncolytic viruses: those that believe intratumoral delivery is necessary for treatment due to potential neutralization of the virus in the bloodstream and those that believe intravenous delivery is also an efficacious means of treatment with a virus. This key publication validates the systemic delivery of oncolytic viruses by proving that oncolytic viruses delivered intravenously can be effective even in the presence of neutralizing antibodies. It sends a message to everyone in the oncology community that systemic delivery of this drug class is not only viable, but may increase its effectiveness in the presence of neutralizing antibodies."
Matt Coffey, president and CEO, Oncolytics Biotech Inc., commenting on research published in Cancer Immunology Research that showed that pelareorep, a systemically delivered oncolytic reovirus, can destroy tumor cells via a monocyte-mediated process even after the virions have been exposed to antibodies designed to neutralize the reovirus
"The microbiome community is enormously complex. Baylor College of Medicine and Texas Children's Hospital have collected vast amounts of data from patients participating in clinical trials; with these carefully assembled collections and those from the first-of-its-kind, randomized, double-blind, placebo-controlled trial run by Rebiotix, we were able to find a way to differentiate patient disease states based on the microbial signature. This has the potential to be an entirely new way of translating complex microbiome data in the context of disease."
Qinglong Wu, Baylor College of Medicine commenting on a collaboration that has resulted in a novel analytical approach to assess patient microbiomes that can differentiate between a dysbiotic, or unhealthy, and restored state
"We asked the question, if you knock out a gene in the T cell – one at a time, all 20,000 – what is the impact of knocking out that gene on the ability of the T cells to get into the tumor? PD-1 scored strongly, so that was reassuring and validated the approach. But we also found a number of other genes that were as good as PD-1 in that model, and a few that were better."
David Meeker, CEO, KSQ Therapeutics Inc., which completed an $80 million series C round to support clinical development of oncology drug candidates generated by the company's CRISPRomics discovery engine